DNDi‘s Strategy for Cutaneous Leishmaniasis
WHAT IS DNDi DOING TO ADDRESS UNMET TREATMENT NEEDS?
For cutaneous leishmaniasis (CL), DNDi’s objective is to develop short, safe, efficacious, affordable, and field-adapted treatments, at least for lesions caused by L. tropica and L. braziliensis. As a medium-term strategy, DNDi is developing a topical treatment based on amphotericin B. In addition, we aim to improve treatment strategies using currently available treatment modalities and will be evaluating a single application of heat therapy combined with a short course of oral miltefosine. In the medium to long term, DNDi aims to develop an oral drug and an immune-modulator for use in combination with chemotherapy. This novel approach aims to initially eliminate parasites with chemotherapy, followed by enhancement of the patient’s immune response with an immune-stimulating agent.
A new topical or oral treatment for CL would ideally be efficacious against all species, show at least 95% efficacy, be easy to use, short course (14-28 days), compatible for combination therapy, produce minimal scarring, be safe in pregnant and breastfeeding women, affordable, and adapted to tropical climates.
DNDi aims to deliver:
- A safe, effective, and shorter-course treatment for CL.